SCHEMBL3853364

SCHEMBL3853364

CCCN1CCC(O)(c2cccc(OC(F)F)c2Cl)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 10/20 0.45
SLC6A1 P30531 1/20 0.41
SLC6A12 P48065 1/20 0.41
SLC6A11 P48066 1/20 0.41
SLC6A13 Q9NSD5 1/20 0.41
MGLL Q99685 2/20 0.40
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
DRD3 P35462 5/20 0.38
HTR1A P08908 1/20 0.38
DRD1 P21728 1/20 0.38
DRD5 P21918 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
HTR7 P34969 1/20 0.38
HRH1 P35367 1/20 0.38
HTR2B P41595 1/20 0.38
DRD4 P21917 1/20 0.38
SIGMAR1 Q99720 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3850817 0.91 DRD2 (0.42) DRD2SLC6A1SLC6A12SLC6A11SLC6A13
SCHEMBL3853285 0.88 SLC6A1 (0.42) DRD2SLC6A1SLC6A12SLC6A11SLC6A13
SCHEMBL3852299 0.84 CCR1 (0.48) DRD2SLC6A1SLC6A12SLC6A11SLC6A13
SCHEMBL3861375 0.80 DRD2 (0.50) DRD2OPRM1OPRL1DRD3HTR1A
SCHEMBL3856142 0.80 DRD2 (0.58) DRD2OPRM1OPRL1DRD3DRD4
SCHEMBL3851762 0.78 SLC6A1 (0.39) DRD2SLC6A1SLC6A12SLC6A11SLC6A13
SCHEMBL3849563 0.77 DRD2 (0.45) DRD2OPRM1OPRL1DRD3HTR1A
SCHEMBL3850813 0.77 OPRM1 (0.46) DRD2OPRM1OPRL1DRD3HTR1A
SCHEMBL3772725 0.76 DRD2 (0.57) DRD2DRD3SLC6A4
SCHEMBL2783370 0.76 DRD2 (0.63) DRD2DRD3HTR1ASLC6A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765779-B1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2009-11-18 EP disclosed
US-7579474-B2 Substituted piperidines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) 2009-08-25 US disclosed
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US disclosed
EP-1765779-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2007-03-28 EP disclosed
WO-2005121092-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, PRLHR, DRD3 DRD2 1/4885SLC6A1 114/4885SLC6A12 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.